To test this hypothesis, we measured the expression of MEG3 in FFA-stimulated hepatocytes, HFD-induced NAFLD mouse model, examined the interactions between MEG3, EZH2, and SIRT6, and assessed the therapeutic potential of overexpressing MEG3. This evidence concerns the gene MEG3 and metabolic dysfunction-associated steatotic liver disease.